Best Precision Medicine Products

EpicCare Ambulatory, one of the top ten ambulatory EHRs in the country, specializes in outpatient primary care. The module is used for documenting visits, placing orders, sending prescriptions, and viewing and communicating test results.

Our unique approach uses complex assays and treatment algorithms to help your doctor prescribe the right high blood pressure drugs that will work for you. With Geneticure, you’ll discover the personalized physiology and genetics associated with your hypertension that show the function of your heart, kidneys and blood vessels. Our method goes beyond most DNA tests that only look at drug metabolizing enzymes — how much of a drug gets into your bloodstream. Drug metabolizing enzymes are primarily used to help guide the correct dosage, independent of whether or not it’s the right medication in the first place. With Geneticure, you’ll find out which medications might be most likely to work best for you, based not only on drug metabolism, but also enzymes, hormonal pathways, and drug receptors in your DNA. Geneticure has 3 clinical trials on nearly 700 subjects demonstrating clinical and health economic utility, with 5 peer reviewed publications.

Phosphorus provides comprehensive genetic testing across most specialties, including: cardiology, lipidology, oncology, neurology, obstetrics and gynecology, fertility, reproductive endocrinology, pharmacology, and more. In addition to operating as a reference lab and conducting genetic testing for your patients, we also provide genetic counseling services. Providers that are interested in moving testing in house, can reach out to our company for lab management and in-house opportunities for partnership.

Using our Geneticure platform, our team of scientists has developed a COVID19 solution, potentially creating an important short-term advance until a vaccine. One of the most common co-morbidities in patients who develop severe illness is hypertension, an area where we have profound expertise in the genetics of the disease and treatment response. Like in hypertension treatment, we have identified genetic influences within the renin-angiotensin-aldosterone system (RAAS) that we believe will be beneficial in predicting the severity of, and guiding treatment for, COVID19 patients. Many companies and academics are tackling this from various angles leaning on their expertise to help save lives and preserve resources, we hope to do the same. Here’s how: COVID-19, like other coronaviruses, bind to and utilize, angiotensin-converting enzyme 2 (ACE2) as a host receptor in order to infect cells resulting in respiratory illness in humans. This is the lock-and-key allowing entry into the cells. As we all have learned, some can carry and transmit the virus without any symptoms, some with mild symptoms, and some with severe enough complications resulting in death. Hypertension can cause changes in the RAAS (as an important counter-regulatory pathway to balance increases in blood pressure) and common blood pressure medications have shown to modulate ACE2 levels in small trials. Several other clinical comorbidities and demographic variables including diabetes, age, and sex have been shown to cause changes in the RAAS in animal models: these are all associated with differences in COVID-19 presentation. Using the data that are available from these patients with varying levels of severity, it is clear that differences in endogenous ACE2 levels may alter the risk of disease transmission along with the degree of severity of disease progression. Not all hypertensives, diabetics, or men develop COVID-19, and many without these factors ultimately develop COVID-19 at varying degrees of severity, suggesting genetics may be one of many factors that is important. Interestingly, there are important potential differences in the importance of ACE2 pre-vs. post-infection. With high ACE2 levels likely being protective for the heart and lungs post-infection. Given this complex relationship: further study is certainly warranted. With our cheek-swab test, we can identify patients who likely have low vs. high ACE2 levels, based on genetic variants important in the RAAS, to triage their risk for disease progression. We are beginning clinical research trials on this. We can also utilize this genetic information to suggest common medication adjustments that can be utilized to reduce ACE2 concentrations, hopefully improving outcomes and saving lives.

Achieve therapeutic targets and improve sample efficiency. InsightRX Nova standardizes precision dosing across your institution, improving efficacy, minimizing variability, and reducing adverse events—all while lowering blood sampling by up to 50%. Improve model accuracy and stay up to date. InsightRX Nova gives you access to the most up to date, clinically validated models developed by our partners and curated from the literature. In addition, dosing guidance improves over time as we update models using our proprietary human-assisted AI framework and data from the InsightRX network. Capture results and outcomes. InsightRX Nova includes reports on your institution’s target performance compared to national benchmarks or your institutional data. For more powerful analytics, InsightRX Apollo provides dashboards enabling you to understand how targets are being met across drugs, providers, and subpopulations.

Our clinical decision support tool synthesizes the evidence impacting drug response, including pharmacogenomic testing, to support doctors and pharmacists in making faster, more proactive decisions at the point of care. YouScript is the only clinical decision support system validated in multiple clinical and real world studied system. In a recent study, utilization of YouScript and pharmacogenomic testing revealed 52% reduction in readmissions and 42% reduction in ED visits. And we’re successfully integrated into the clinical workflow of Epic, Cerner, Allscripts, and Telus Health. Equally important is that our team includes pioneers in genetics, medicine, technology, and genetic counseling, and is trusted by experts to provide the most comprehensive, reliable genetic screening, technology, and support available. In pursuit of our mission, we aim to be a trusted partner to value-based healthcare organizations, providers, and payers who want to lower the barriers of precision medicine through transforming clinical decisions through genomics.

The RightMed Test is a PGx test that offers comprehensive coverage backed by rigorous curation of high-level, scientific evidence to give providers and their patients confidence in test results. The RightMed Test covers 27 genes that may impact how a patient responds to certain medications used to treat various conditions including psychiatric conditions, cancer, cardiovascular disease, pain, and more.

A digital health platform, powered by genomic data, for the use of life insurance clients. For life insurers - we provide personalized and effective tools to extend their customers' life expectancy, thus increasing retention and decreasing claims. For life insurance clients - we provide a gamified and personalized experience using their personal DNA, that motivates them to act upon their health. Life insurance clients that use our system are more engaged and live a longer, healthier life. Customer’s privacy is our domain. Our post underwriting solutions are 100% regulatory compliant, we are the Regulatory Firewall. The future is now, Futura Genetics.

500 proprietary risk assessment algorithms focused on early disease risk detection to improve early disease and diagnosis.